Literature DB >> 8369990

Misoprostol, a prostaglandin E1 analogue, inhibits basic calcium phosphate crystal-induced mitogenesis and collagenase accumulation in human fibroblasts.

G M McCarthy1, P G Mitchell, H S Cheung.   

Abstract

Synovial fluid basic calcium phosphate (BCP) crystals are associated with severe destructive arthropathy. BCP crystals induce the secretion of matrix-degrading enzymes such as collagenase. No prophylactic or therapeutic agents are recognized to ameliorate the cartilage damage associated with BCP deposits in joints. As a chondroprotective effect of prostaglandins (PG) has been suggested, we studied the effect of misoprostol, a PGE1 analogue, on BCP crystal-induced mitogenesis and collagenase messenger RNA (mRNA) accumulation in human fibroblasts (HF). Mitogenesis was determined by 3H-thymidine incorporation assays and collagenase mRNA accumulation by Northern blot analysis, in HF stimulated with BCP crystals in the presence or absence of misoprostol. Misoprostol caused concentration-dependent inhibition of BCP crystal-induced mitogenesis. The inhibition of BCP-stimulated mitogenesis was not specific as misoprostol also inhibited the mitogenic response to 10% serum. There was only 50 (+/-5)% inhibition of serum-induced mitogenesis by misoprostol at 500 ng/ml, the concentration that completely inhibited BCP crystal-induced mitogenesis. Misoprostol also inhibited the accumulation of collagenase mRNA in BCP-stimulated HF by 63%. These data suggest that misoprostol may inhibit the synovial proliferation and cartilage degradation that accompany BCP crystal deposition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8369990     DOI: 10.1007/bf00571332

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  19 in total

Review 1.  Prostaglandin E1: is it useful?

Authors:  R B Zurier
Journal:  J Rheumatol       Date:  1990-11       Impact factor: 4.666

2.  The prostaglandin paradox: additive inhibition of neutrophil function by aspirin-like drugs and the prostaglandin E1 analog misoprostol.

Authors:  E A Kitsis; G Weissmann; S B Abramson
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

3.  A method for isolation of intact, translationally active ribonucleic acid.

Authors:  G Cathala; J F Savouret; B Mendez; B L West; M Karin; J A Martial; J D Baxter
Journal:  DNA       Date:  1983

4.  "Milwaukee shoulder"--association of microspheroids containing hydroxyapatite crystals, active collagenase, and neutral protease with rotator cuff defects. I. Clinical aspects.

Authors:  D J McCarty; P B Halverson; G F Carrera; B J Brewer; F Kozin
Journal:  Arthritis Rheum       Date:  1981-03

5.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

6.  Modulation of prostaglandin E2 synthesis in rabbit synoviocytes.

Authors:  R J Rothenberg
Journal:  Arthritis Rheum       Date:  1987-03

7.  Mitogenic activity of hydroxyapatite: requirement for somatomedin C.

Authors:  H S Cheung; J J Van Wyk; W E Russell; D J McCarty
Journal:  J Cell Physiol       Date:  1986-08       Impact factor: 6.384

8.  Possible role of prostaglandins as negative regulators in growth stimulation by tumor necrosis factor and epidermal growth factor in human fibroblasts.

Authors:  T Hori; S Kashiyama; M Hayakawa; S Shibamoto; M Tsujimoto; N Oku; F Ito
Journal:  J Cell Physiol       Date:  1989-11       Impact factor: 6.384

9.  Suppression of human synovial cell proliferation by dihomo-gamma-linolenic acid.

Authors:  D G Baker; K A Krakauer; G Tate; M Laposata; R B Zurier
Journal:  Arthritis Rheum       Date:  1989-10

10.  Prostaglandins antagonize fibroblast proliferation stimulated by tumor necrosis factor.

Authors:  T Hori; Y Yamanaka; M Hayakawa; S Shibamoto; M Tsujimoto; N Oku; F Ito
Journal:  Biochem Biophys Res Commun       Date:  1991-01-31       Impact factor: 3.575

View more
  1 in total

Review 1.  Phosphocitrate as a potential therapeutic strategy for crystal deposition disease.

Authors:  H S Cheung
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.